Navigation Links
Alexza's Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference
Date:3/23/2009

se 3 clinical trials, and is projecting a New Drug Application submission in early 2010. The Company has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine), and it has advanced AZ-104 (Staccato loxapine) into Phase 2b testing, both product candidates being developed for the acute treatment of migraine headache. AZ-002 (Staccato alprazolam) has completed Phase 1 testing and a Phase 2a proof-of-concept clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement

The anticipated presentations will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertak
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
3. Vical Names Andrew de Guttadauro Vice President, Corporate Development
4. Signalife Provides Corporate Update
5. Biomira Announces Plan to Reincorporate in the United States
6. Pressure BioSciences, Inc. Provides Corporate Update
7. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
8. Clinsys Clinical Research, Inc. Announces Relocation of Corporate Headquarters
9. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 2014 Lawrence Livermore National ... (WIB) and Las Positas College (LPC) recently established ... and hands-on training for veterans, officials recently announced. ... Las Positas is designed to help veterans ... technician careers, and establishes a pipeline of qualified ...
(Date:7/21/2014)... a chain of carbon atoms can turn it from ... University scientists. , Stretching the material known as carbyne ... by just 3 percent can begin to change its ... mechanically activated nanoscale electronics and optics. , The finding ... appears in the American Chemical Society journal Nano ...
(Date:7/21/2014)... EUGENE, Ore. (July 21, 2014) The yield ... of Oregon have developed a low-energy, solution-based mineral substitution ... that could find use in electronics and alternative energy ... on the cover of the July 21 issue of ... most citations of research in the inorganic and nuclear ...
(Date:7/21/2014)... York , July 21, 2014 ... on Global & USA ... Trends, and Forecasts ResearchMoz presents this ... Biomaker Market   to 2018 (Identification, Technologies, Market Analysis, ... Trends, and Pipeline Analysis. GLOBAL & ...
Breaking Biology Technology:Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3Carbyne morphs when stretched 2Carbyne morphs when stretched 3Oregon chemists eye improved thin films with metal substitution 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 3Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 4Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 5Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 6
... Oncology Biomarkers, FREMONT, Calif., Feb. 6 ... high-value molecular diagnostics company, today announced,the renewal ... University,on the development of novel biomarkers that ... monitoring of prevalent cancers, including,ovarian, breast and ...
... BRL ) today announced that its subsidiary, Barr ... Co., Inc.,s Fosamax(R),(Alendronate Sodium) Tablets, 70 mg after receiving ... The FDA approved the Company,s application on February ... the,earliest to expire of the patents listed with the ...
... 6 Iomai Corporation,(Nasdaq: IOMI ) today announced ... officer, will present at the 10th Annual BIO,CEO & ... 12. Mr. Erck,s,presentation will begin at 2 p.m. Eastern ... Mr. Erck will give an update on corporate ...
Cached Biology Technology:Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests 2Barr Launches Generic Fosamax(R) Tablets, 70 mg 2Barr Launches Generic Fosamax(R) Tablets, 70 mg 3Barr Launches Generic Fosamax(R) Tablets, 70 mg 4Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12 2
(Date:7/22/2014)... showed that mutations in prickle genes cause epilepsy, ... by repeated seizures over time. However, the mechanism ... A new University of Iowa study, published online ... National Academy of Sciences , reveals a novel ... have identified the basic cellular mechanism that goes ...
(Date:7/22/2014)... research in the Journal of Clinical ... signaling and dopamine transporter function are linked ... Parkinsonism and attention deficit hyperactivity disorder (ADHD). ... critical basis for further exploration of how ... contribute to brain disorders" said Michelle Sahai, ...
(Date:7/22/2014)... on July 14, 2014, by lightning from a weather system ... of four fires: Stokes Fire, Gold Hikes Fire, French Creek ... fires are now one larger fire. The fires are burning ... over 243,000 acres in size. The present fire situation ... Public and firefighter safety is the priority on the Carlton ...
Breaking Biology News(10 mins):UI study finds potential genetic link between epilepsy and neurodegenerative disorders 2The dopamine transporter 2The dopamine transporter 3
... from early hominid to dominant species, is the defining ... To chronicle this epic narrative an internationally renowned team, ... University, presents the Wiley-Blackwell Encyclopedia of Human Evolution, a ... history. Over two volumes and 5000 entries ...
... Boston, MA - Some 25 million people in the United ... diseases characterized by often debilitating pain in the joints. Now ... gel that could spell the future for treating these diseases ... the targeted release of medicine at an affected joint, and ...
... crustaceans called copepods rule the world, at least when ... numerous multi-cellular organisms in the seas, copepods are an ... webs. To understand and predict how copepods respond ... how many new copepods are born, but how many ...
Cached Biology News:Injectable gel could spell relief for arthritis sufferers 2Injectable gel could spell relief for arthritis sufferers 3Death -- not just life -- important link in marine ecosystems 2
... Schistosomal glutathione-S-transferase (GST) is commonly used ... in E. coli (1). The GSTTag sequence ... and in some cases the solubility of ... soluble, properly folded form, GSTTag fusion proteins ...
... your samples with eArray and Agilents custom printing. ... own microarray designs that meet your specific biological ... delivery of your arrays in weeks, anywhere in ... creation application tool that enables you to design ...
Acetylcholinesterase (human brain, AChE)...
... 7500ce meets the demands of the routine ... performance from reliable, robust and simple to ... power in the most challenging sample matrices ... equally suited to the toughest analytical challenges ...
Biology Products: